UNSPSC 51433400: Antihypertensive nicotinic acids

Antihypertensive drugs made from 2-, 3-, or 4-Pyridinecarboxylic acids, pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position.

UNSPSC 51433400 Antihypertensive nicotinic acids, a Class code, covers the procurement of cardiovascular and antihypertensive medications used in emergency medical services, institutional health care, and pharmacy benefit programs. State and local governments soliciting under this code are acquiring specific pharmaceutical products for emergency response, patient care, and managed pharmacy programs. The issuing bodies span city fire rescue departments, state health agencies, and multistate cooperative purchasing alliances that aggregate demand across state and local facilities. Scope ranges from individual medication line items with specific unit counts and packaging requirements to bulk generic pharmaceutical supply agreements serviced through authorized wholesalers, all subject to Good Manufacturing Practices certification, FDA compliance, expiration-date management, and OSHA hazard communication standards.

Recent activity centers in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications, due April 8, 2026, requiring four specific medication SKUs (Labetalol HCI 100mg vials, Epinephrine 1:10,000 injections, Adenosine 6mg vials, Diltiazem 25mg vials) totaling roughly $40,000 with a Small Local Business Enterprise set-aside and 5 percent bid discount for SLBE participation. The Texas Health and Human Services Commission released RFI HHS0017013 on March 27, 2026, to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity for self-insured group health plans and state agencies outside traditional PBM and GPO channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with awarded vendors required to supply through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, effective July 1, 2026.